Sequenom, Inc. Announces The Availability Of Heredi-T™ Cystic Fibrosis Carrier Screening LDT Through Sequenom CMM

Sequenom, Inc. Announces The Availability Of Heredi-T™ Cystic Fibrosis Carrier
                      Screening LDT Through Sequenom CMM

PR Newswire

SAN DIEGO, March 21, 2013

SAN DIEGO, March 21, 2013 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a
life sciences company providing innovative genetic analysis solutions, today
announced that Sequenom Center for Molecular Medicine (SCMM) has launched an
advanced new cystic fibrosis carrier screen test branded under the name
Heredi-T™. The laboratory-developed test (LDT) is now available as a testing
service to ordering physicians.

The Heredi-T Cystic Fibrosis (CF) test analyzes 136 mutations and five
variants proven to be clinically relevant in causing CF, integrating disease
causing mutations selected from the Johns Hopkins CFTR2 database
( The LDT analyzes nearly six times the number of
mutations currently available in other screening methods and can be performed
preconception or at any time during pregnancy with a DNA sample obtained from
a buccal swab. 

"The Heredi-T test provides significant new clinical value, offering highly
reliable information about a patient's risk of being a cystic fibrosis
carrier," said Bill Welch, President and COO of Sequenom. "This introduction
adds to Sequenom CMM's leadership in prenatal testing and supports our mission
to help health care providers and their patients make more informed clinical
decisions through the use of advanced genetics."

The American College of Obstetricians and Gynecologists (ACOG) recommends
cystic fibrosis carrier screening for all patients. According to ACOG,
additional screening consideration should be given to patients with the
following, as these clinical indicators increase the risk of CF:

  oFamily history of CF in the patient or partner's family
  oUltrasound findings that indicate an increased risk for CF
  oBowel or dilated loops of bowel
  oHistory of male infertility

Results of the Heredi-T CF test are delivered to the physician on average
within seven business days. A positive Heredi-T CF test result indicates that
the patient has one copy of a genetic mutation that is known to cause CF, and
they should be advised to consider genetic counseling or further testing. A
negative Heredi-T CF test result indicates a low risk for CF, but does not
completely eliminate the risk because the test does not screen for all
possible CF mutations.

About Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common genetic diseases in the United
States. It is caused by changes in the CFTR gene. Changes in this gene cause
the body to produce thick sticky mucus in the lungs, pancreas and other organs
that can affect breathing and digestion. Symptoms can range from moderate to
severe and can even impact fertility. It is estimated that more than 10
million Americans are carriers of CF. While the risk of being a CF carrier is
dependent upon one's ethnicity and family history, individuals of all racial
and ethnic groups may be carriers of CF.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and
CLIA-certified molecular diagnostics laboratory, has developed a broad range
of laboratory tests with a focus on prenatal and ophthalmological diseases and
conditions. Branded under the names MaterniT21™ PLUS, Heredi-T™, SensiGene®
and RetnaGene™, these molecular genetic laboratory tests provide early patient
management information for obstetricians, geneticists, maternal fetal medicine
specialists, retina specialists and ophthalmologists. Sequenom CMM is
changing the landscape in genetic disorder diagnostics using proprietary
cutting edge technologies. Visit http://www.sequenomcmm.comfor more
information on laboratory testing services.

SEQUENOM^®, SEQUENOM^® CMM^® , MaterniT21™ PLUS, Heredi-T™, SensiGene^® and
RetnaGene™ are trademarks of Sequenom, Inc. All other trademarks and service
marks are the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the expected benefits,
impact, and value of the Heredi-T™ CF test to healthcare providers and their
patients, the Company's commitment to improving healthcare through
revolutionary genetic analysis solutions, and Sequenom CMM's impact on the
landscape in genetic diagnostics, are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
the risks and uncertainties associated with market demand for and acceptance
and use of technology and tests such as the Heredi-T™ CF test, reliance upon
the collaborative efforts of other parties such as, without limitation,
healthcare providers, international distributors and licensees, the Company or
third parties obtaining or maintaining regulatory approvals that impact the
Company's business, government regulation particularly with respect to
diagnostic products and laboratory developed tests, publication processes, the
performance of designed product enhancements, the Company's ability to develop
and commercialize technologies and products, particularly new technologies
such as noninvasive prenatal diagnostics, laboratory developed tests, and
genetic analysis platforms, the Company's financial position, the Company's
ability to manage its existing cash resources or raise additional cash
resources, competition, intellectual property protection and intellectual
property rights of others, litigation involving the Company, and other risks
detailed from time to time in the Company's most recently filed Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012, its most
recently filed reports on Form 8-K, and its most recently filed Annual Report
on Form 10-K, and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. These forward-looking statements are based
on current information that may change and you are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and the Company undertakes no
obligation to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,, Jakob Jakobsen,
Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.